Naysayers question Genenvax

Genentech Inc.'s plans for a spinoff, Genenvax Inc., to run Phase III trials of its gp120 AIDS vaccine, has sparked dissent in certain quarters of the clinical research community.

GNE last month announced that it plans to invest $2 million in the new company, which hopes to raise $18 million from private investors, in order to run studies in the U.S. and Thailand (see BioCentury, Feb. 26)...